Predictors of response in patients with active Crohn's disease treated with certolizumab pegol: A multiple regression analysis of PRECISE 2 data

被引：0
|
作者：
Hanauer, Stephen B.
Schreiber, Stefan
Thomsen, Ole O.
Lichtenstein, Gary R.
Bloomfield, Ralph
Sandborn, William J.
机构：
来源：
GASTROENTEROLOGY | 2008年 / 134卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A489 / A490
页数：2
相关论文
共 50 条
  • [1] Predictors of Endoscopic Response and Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Logistic Regression Analysis of the Music Data
    Colombel, Jean-Frederic
    Lemann, Marc
    Allez, Matthieu
    Mitchev, Krassimir
    Jamoul, Corinne
    Hebuterne, Xavier
    [J]. GASTROENTEROLOGY, 2009, 136 (05) : A181 - A181
  • [2] Certolizumab pegol improves HRQoL in patients with Crohn's disease: Data from PRECiSE 2
    Feagan, B.
    Keininger, D.
    Coteur, G.
    Schreiber, S.
    [J]. INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 661 - 662
  • [3] Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert R.
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Ernault, Etienne
    Fedorak, Richard N.
    Spehlmann, Martina
    Wolf, Douglas C.
    Lee, Scott D.
    Rutgeerts, Paul J.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S164 - S164
  • [4] Fecal Calprotectin Concentration and Clinical Response to Certolizumab Pegol in Patients with Active Crohn's Disease: Results from PRECiSE 2
    Sandborn, William
    Pierre-Louis, Bosny
    Ullman, Thomas
    Binion, David
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S453 - S453
  • [5] Fecal calprotectin concentration and clinical response to certolizumab pegol in patients with active Crohn's disease: results from PRECiSE 2
    Sandborn, William J.
    Pierre-Louis, Bosny
    Ullman, Thomas A.
    Binion, David G.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S24 - S25
  • [6] Certolizumab Pegol for Active Crohn's Disease Reply
    Sandborn, William J.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (03) : 327 - 328
  • [7] Response to certolizumab pegol induction is not steroid-dependent in patients with active Crohn's disease
    Hommes, Daniel W.
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A494 - A494
  • [8] Fecal Calprotectin Concentration and Clinical Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: Results from PRECiSE 1
    Sandborn, William
    Ullman, Thomas
    Pierre-Louis, Bosny
    Binion, David
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S441 - S441
  • [9] Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
    Wade, Janet R.
    Parker, Gerry
    Kosutic, Gordana
    Feagen, Brian G.
    Sandborn, William J.
    Laveille, Christian
    Oliver, Ruth
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 866 - 874
  • [10] Changes in utility scores of patients with active Crohn's disease after certolizumab pegol 400 mg induction and maintenance (PRECiSE 2)
    Tan, Seng
    Feagan, Brian G.
    Schreiber, Stefan
    Brown, Martin C. J.
    Gerlier, Laetitia C.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S485 - S485
12345